Document |
Document Title |
WO/2024/042163A1 |
Disclosed herein are compounds of the formula (I), or pharmaceutically acceptable salts thereof: (I) wherein R1 and R2 independently represent a hydrogen atom or a deuterium atom; R3 represents a hydrogen atom or a -COOH group; R3' repre...
|
WO/2024/044621A1 |
Various aspects described herein relate to a functionalized nanoscale substrate. The functionalized nanoscale substrate includes a functionalized surface of the substrate that includes a boronated portion.
|
WO/2024/041440A1 |
Provided tricyclic heterocyclic derivatives as shown in Formulas (IA) and (IB), pharmaceutical compositions comprising them, a process for their preparation, and their use as therapeutic agents.
|
WO/2024/040681A1 |
The present invention relates to an uPAR-targeted third-generation chimeric antigen receptor, immune effector cells (e.g., T cells, NK cells) engineered to express the chimeric antigen receptor of the present invention, and a use of the ...
|
WO/2024/041236A1 |
A fusion protein ANGPTL3 monoclonal antibody-B comprising an ANGPTL3 monoclonal antibody is formed by fusing the ANGPTL3 monoclonal antibody with a sequence B. The fusion protein ANGPTL3 monoclonal antibody-B is used for treating disease...
|
WO/2024/041652A1 |
The present disclosure provides a method of cancer treatment or enhancing an immune response, the method comprising administering to a patient an effective amount of anti-Lag3 antibody or antigen binding fragment thereof alone or in comb...
|
WO/2024/041639A1 |
The present disclosure relates to an antibody, such as a monoclonal antibody (mAb), or an antigen-binding fragment thereof, that specifically recognizes TIGIT, and methods of making the same and using the same.
|
WO/2024/042220A1 |
The present invention relates to isolated polypeptides derived from stanniocalcin-2 (STC2), and polypeptide fragments and variants thereof useful for inhibiting proteolytic activity of the pregnancy-associated plasma protein-A (PAPP-A), ...
|
WO/2024/043252A1 |
This pharmaceutical containing, collectively or separately as a combination, an antibody having immunological reactivity with respect to CAPRIN-1 protein or a fragment of said antibody, and an epidermal growth factor receptor (EGFR) inhi...
|
WO/2024/043258A1 |
This pharmaceutical product is useful for the treatment and/or prevention of cancer and contains the following components combined with each other in a blended or separated form: an antibody or a fragment thereof having immunological rea...
|
WO/2024/044780A1 |
The present disclosure provides IL-18 polypeptides with one or more mutations, pharmaceutical compositions, diagnostic compositions, and kits containing the polypeptides, nucleic acids and expression vectors encoding the polypeptides, ce...
|
WO/2024/041519A1 |
Provided is a morpholinyl quinazoline compound represented by formula I, or a pharmaceutically acceptable salt, a solvate, a polymorph or a prodrug thereof. The morpholinyl quinazoline compound has a dual inhibitory activity against PI3K...
|
WO/2024/041543A1 |
Provided is a method of preparing antibody with thiol group site-specific modifications and use of TCEP. The thiol group(s) is/are reduced from the interchain disulfide bonds within the antibody, and the method comprises using TCEP or a ...
|
WO/2024/042483A1 |
The present invention relates to methods of treating leukemia using Tyrosine Kinase inhibitors. The invention particularly relates to methods of treating CML and ALL using a compound of Formula I or a pharmaceutically acceptable salt the...
|
WO/2024/044552A1 |
Described herein are immunoconjugates comprising an: a) antigen binding region; b) an immunoglobulin heavy chain constant region; and c) a radioisotope chelating agent; wherein the molecular weight of said immunoconjugate is between 60 a...
|
WO/2024/041643A1 |
The present disclosure relates to a fused tricyclic compound, a preparation method therefor, and medical use thereof. Specifically, the present disclosure relates to a fused tricyclic compound represented by general formula (I), a prepar...
|
WO/2024/044713A1 |
The present disclosure relates to compounds and compositions for inhibition of RAF serine/threonine protein kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers.
|
WO/2024/044731A1 |
The invention provides diazepino-thieno-quinoxaline compounds, pharmaceutical compositions, their use for inhibiting MK2, and their use in the treatment of a disease or condition, such as an inflammatory disorder.
|
WO/2024/044486A1 |
Described herein are compounds that are JAK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of diseases or conditi...
|
WO/2024/044551A1 |
Described herein are immunoconjugates comprising a multivalent antibody and a chelating agent, wherein the multivalent antibody comprises a polypeptide comprising: a first antigen-binding domain; and a second antigen-binding domain.
|
WO/2024/042316A1 |
This invention relates to novel compounds and pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as inhibitors of discoidin domain receptor 1 (DDR1) and discoidin doma...
|
WO/2024/040728A1 |
Provided are a platinum-based drug carbon nanodot and a method for preparing same and a carbon nanodot protein compound and use thereof. The platinum-based drug carbon nanodot comprises a carbon-based core having the characteristic of vi...
|
WO/2024/041477A1 |
Provided is use of a multi-domain fusion protein in the preparation of a medicament for treating or preventing tumors. The fusion protein comprises an anti-PD-L1 single-domain antibody fragment, a VEGF-antagonizing fragment and a TGF-β ...
|
WO/2024/044779A2 |
Provided are Delta-like ligand 3 (DLL3) -binding molecules, in particular, to human antibodies specific for DLL3, including antibody fragments. Also provided are recombinant receptors, including chimeric antigen receptors (CARs) that con...
|
WO/2024/041586A1 |
The present invention relates to a prodrug containing a JAK inhibitor, a composition, and use thereof . In particular, the present invention relates to a compound represented by formula (II), a pharmaceutical composition containing the c...
|
WO/2024/041415A1 |
A collagenase liposome inhalant, used for treating pulmonary fibrosis after pulmonary inhalation. Use of a collagenase liposome in the preparation of an inhalant for treating pulmonary fibrosis, and a preparation method for the collagena...
|
WO/2024/041535A1 |
The present disclosure relates to a nano-composition, a preparation method therefor, and use thereof. The nano-composition is formed by self-assembly of an oligopeptide containing a tryptophan dipeptide motif and cisplatin. The general f...
|
WO/2024/041744A1 |
Combination therapies for use in the treatment of brain tumours, particularly glioma and embryonal brain tumours. Disclosed herein are pharmaceutical compositions comprising a complex of Panobinostat and a cyclodextrin, a second pharmace...
|
WO/2024/041545A1 |
The present disclosure relates to a novel thiol reductant having the formula (I), the preparation and the use in antibody modification.
|
WO/2024/041761A1 |
The present invention refers immune cells expressing a TCR and a co-stimulatory. In particular, the invention refers to immune cells expressing a (i) T cell receptor (TCR) specific for a TCR specific for NY-ESO-1 peptide SLLMWITQC and (i...
|
WO/2023/250499A9 |
The present disclosure provides a chimeric antigen receptor (CAR) molecule comprising a modified hinge and transmembrane domain (HTM-1), wherein the modified hinge and transmembrane domain comprises the amino acid sequence of SEQ ID NO:2...
|
WO/2024/042231A1 |
The present invention relates to an adenovirus or a fragment thereof for use as an adjuvant for the treatment of cancer in a subject in need thereof. The active ingredient is an anticancer agent, preferably an oncolytic virus. The presen...
|
WO/2024/042523A1 |
The present disclosure concerns formulations for oral delivery of at least one active agent of a compound according to formula (I) and/or (II) for the treatment of glycogen storage diseases, neurodegenerative disorders and autophagy-rela...
|
WO/2024/041589A1 |
Disclosed are a nitrogen-containing heterocyclic compound, a preparation method therefor, an intermediate thereof, and use thereof. Specifically, the present invention provides a nitrogen-containing heterocyclic compound as represented b...
|
WO/2024/044344A1 |
The invention provides pyridinylsulfonamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condi...
|
WO/2024/041634A1 |
The present disclosure provides a compound having USP1 inhibitory activity or functionality and a pharmaceutically acceptable salt thereof. The present disclosure further provides a pharmaceutical composition comprising the compound repr...
|
WO/2024/042539A1 |
The present disclosutre provides a compound of Formula (I), its stereoisomers, intermediates, or pharmaceutically acceptable salt thereof and a method of preparation of the same. In addition, the present disclosure provides a pharmaceuti...
|
WO/2024/040300A1 |
The present application generally relates to the identification of certain agonist anti-CD40 antibodies. Based thereon, the invention provides novel agonist antibodies, and the use thereof in therapy.
|
WO/2024/042318A1 |
The invention relates to chimeric antigen receptors (CARs) per se, to CAR constructs, and to T-cell receptor (TCR) beta-chain variable region beta (TCRVβ) CARs. The invention relates to the use of the CARs in immunotherapy, for example ...
|
WO/2024/041435A1 |
The present invention relates to an anti-Her2/CD3 bispecific antibody specifically activated in a tumor microenvironment. Specifically, provided is a bispecific antibody capable of being chemically conjugated to a substrate that is highl...
|
WO/2024/041608A1 |
The present invention relates to a crystal form of a compound N-cyclopropyl-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyri
din-3-yl)methyl)piperazin-1-yl)pyridine carboxamide and a preparation method therefor, and the use thereof in the ...
|
WO/2024/041559A1 |
The invention is directed to a series of novel heterobicyclic amide derivatives as EP4 receptor antagonists which are useful for treating diseases or conditions mediated by the action of PGE2 at EP4 receptors, such as pain, an inflammato...
|
WO/2024/044549A1 |
Described herein are immunoconjugates comprising an: a) antigen binding region; b) an immunoglobulin heavy chain constant region; and c) a radioisotope chelating agent; wherein the molecular weight of said immunoconjugate is between 60 a...
|
WO/2024/044548A1 |
Described herein are approved products and methods of using approved products for treating relapsed and refractory multiple myeloma in a patient. Also described herein are methods of selling or offering for sale an approved product.
|
WO/2024/044550A1 |
Described herein are heavy chain antibodies that bind to DLL3 and immunoconjugates of DLL3 heavy chain antibodies useful for cancer therapy.
|
WO/2024/040897A1 |
The present invention relates to a transdermal formulation for single use of an immunomodulatory imide compound comprising thalidomide or an analogue thereof and combined use with dexamethasone, a preparation method therefor, and use the...
|
WO/2024/041629A1 |
The present invention provides a preparation method for R-type ketorolac and use thereof, and belongs to the technical field of organic synthesis. The preparation method comprises the following steps: step 1, preparing ketorolac; and ste...
|
WO/2024/044730A1 |
The invention provides pyrazolylsulfonamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condi...
|
WO/2024/042185A1 |
Disclosed herein are compounds of the formula (I), or pharmaceutically acceptable salts thereof: wherein R1 and R2 independently represent a hydrogen atom or a deuterium atom; R3' and R3" independently represent a hydrogen atom, a methyl...
|
WO/2024/040668A1 |
A Palbociclib saccharinate crystal form and a preparation method therefor. A prepared Palbociclib saccharinate crystal form α has excellent physical and chemical stability, high solubility, and good dissolution, fluidity and bioavailabi...
|